Literature DB >> 16796531

Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines.

Sushila K Nordone1, James W Peacock, Shaun M Kirwan, Herman F Staats.   

Abstract

Immunization by the nasal route is an established method for the induction of mucosal and systemic humoral and cell-mediated antigen-specific responses. However, the effectiveness of nasal immunization is often hampered by the need for increased doses of antigen. Bioadhesives and absorption enhancers were investigated for their ability to enhance immune responses in mice after nasal immunization with model HIV-1 peptide and protein immunogens. Two additives, hydroxypropylmethylcellulose (HPMC) and capric acid, consistently enhanced antigen-specific serum IgG endpoint titers under conditions in which antigen dose was limiting. Nasal immunization of mice with 20 microg of an HIV-1 peptide immunogen plus cholera toxin (CT) as adjuvant induced serum antipeptide IgG titers of 1:9.5log2 after four immunizations while the addition of CA or HPMC to the vaccine formulation increased serum antipeptide IgG titers to 1:15.4log2 and 1:17.6log2, respectively. When 5 microg recombinant HIV-1 gp41 was used as the immunogen, the addition of CA or HPMC to the vaccine formulation increased serum anti-gp41 IgG titers to 1:11.6log2 and 1:8.8log2, respectively, compared to 1:5.2log2 after three nasal immunizations with 5 microg gp41 + CT alone. Thus, HPMC and capric acid may be useful additives that increase the immunogenicity of nasally administered vaccines and permit less antigen to be used with each immunization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796531     DOI: 10.1089/aid.2006.22.558

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  An entirely cell-based system to generate single-chain antibodies against cell surface receptors.

Authors:  Barbara D Lipes; Yu-Hsun Chen; Hongzheng Ma; Herman F Staats; Daniel J Kenan; Michael Dee Gunn
Journal:  J Mol Biol       Date:  2008-04-07       Impact factor: 5.469

2.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

3.  In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.

Authors:  Herman F Staats; S Munir Alam; Richard M Scearce; Shaun M Kirwan; Julia Xianzhi Zhang; William M Gwinn; Barton F Haynes
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

4.  The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.

Authors:  Afton L McGowen; Laura P Hale; Christopher P Shelburne; Soman N Abraham; Herman F Staats
Journal:  Vaccine       Date:  2009-04-14       Impact factor: 3.641

5.  Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.

Authors:  Herman F Staats; Shaun M Kirwan; Carol C Whisnant; James L Stephenson; Diane K Wagener; Partha P Majumder
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

6.  Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Authors:  Herman F Staats; Jeffrey R Fielhauer; Afton L Thompson; Alice A Tripp; Ashley E Sobel; Massimo Maddaloni; Soman N Abraham; David W Pascual
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

Review 7.  Modulation of HIV-1 immunity by adjuvants.

Authors:  M Anthony Moody
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

8.  Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.

Authors:  Ashley L St John; Hae Woong Choi; Q David Walker; Bruce Blough; Cynthia M Kuhn; Soman N Abraham; Herman F Staats
Journal:  NPJ Vaccines       Date:  2020-02-05       Impact factor: 7.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.